Many drugs are promiscuous and bind to multiple targets. On the one hand, these targets may be linked to 17 unwanted side effects, but on the other, they may achieve a combined desired effect (polypharmacology) or 18 represent multiple diseases (drug repositioning). With the growth of 3D structures of drug-target complexes, 19 it is today possible to study drug promiscuity at the structural level and to screen vast amounts of drug-20 target interactions to predict side effects, polypharmacological potential, and repositioning opportunities. 21 Here, we pursue such an approach to identify drugs inactivating B-cells, whose dysregulation can function 22 as a driver of autoimmune diseases. Screening over 500 kinases, we identified 22, whose knock out impeded 23 the activation of B-cells. Among these 22 is the gene KDR, whose gene product VEGFR2 is a prominent 24 cancer target with anti-VEGFR2 drugs on the market for over a decade. The main result of this study is 25 that structure-based drug repositioning for the identified kinase targets revealed the cancer drug ibrutinib 26 as micromolar VEGFR2 inhibitor with a very high therapeutic index in B-cell inactivation. These findings 27 suggest that ibrutinib is not only acting on the Bruton's tyrosine kinase BTK, against which it was designed. 28 Instead, it may be a polypharmacological drug, which additionally targets angiogenesis via inhibition of 29 VEGFR2. Therefore ibrutinib carries the potential to treat other VEGFR2 associated disease. Structure-30 based drug repositioning explains ibrutinibs anti VEGFR2 action through a specific pattern of interactions 31 shared between BTK and VEGFR2. Overall, structure-based drug repositioning was able to predict these 32 findings at a fraction of the time and cost of a conventional screen. 33 35 10000 interfaces [2] and Gao et al. reduce this number to 1000 distinct interface types [10]. While the exact 36
Introduction 34
The number of ways a drug can interact with its target is limited. Alex et al. estimate that there are Table 1 ). Among those five is VEGFR2, which is a key cancer target with approved drugs. Clinical trials 141 are ongoing with exploring the inhibition of VEGFR2 as treatment for psoriasis (pazopanib, phase 1) and 142 systemic scleroderma (nintedanib, phase 3). The other four targets with a link to autoimmunity are DAPK1 143 (inflammatory bowel disease), MST4 (Grave's disease), PXK (systemic lupus erythematosus), and IRAK3 144 (rheumatoid arthritis) (for literature evidence check supplementary Table S1 ). 145 To assess the 22 kinases' potential as drug targets we consulted the Open Targets Platform [5] , which 146 covers over 20.000 targets with associated information on drugs and clinical trials. VEGFR2, EPHB4, 147 CDC7, MAP2K2, and MAP3K10 are listed with VEGFR2 as most established target with a number of 148 drugs already approved. Furthermore, we checked BindingDB [12] , the largest database for drug-target 149 binding affinities and found 22 drugs, each binding one or more of the 22 targets. 14 of the 22 kinases 150 have at least one inhibitor in micromolar range and all but six drugs are polypharmacological drugs hitting multiple targets. In fact, 15 FDA approved drugs inhibit the same 13 kinases including VEGFR2, which 152 documents the polypharmacological potential of these drugs. Most of these drugs are chemically closely 153 related. Consider for example, erlontinib, vandetanib, and gefitinib (see Figure 4 .A for their chemical 154 structure), which belong to the same chemical class of quinazolines. To find a different compound with a 155 better profile of toxicity and specificity we aimed to expand the scaffold space by running a structure-based 156 drug repositioning screen. summarizes the result. Only one compound, Ibrutinib, displays strong inhibition at 10 and 1 µM on one 176 of the kinase (VEGFR2); while 9 other compounds show strong inhibition at 10 µM only. Ten additional 177 compounds show weak inhibition at 10 µM.
178
Thus, taking all analyses together, we have identified a total of 42 drugs Figure 4 , 22 known and 20 179 predicted and validated, which target at least one of the 20 target kinases and which thus carry the potential 180 to inactivate B-cells. Before testing this potential, we summarize the chemical and disease space captured 181 through these 42 drugs.
182
Chemical and disease space of identified drugs. Figure 5 shows a drug-target-disease network for 183 the 42 drugs. The network depicts nicely that the majority of known drugs are used in cancer and are 184 promiscuously targeting multiple targets. This is complemented by tofacitinib, an autoimmunity drug 185 targeting many shared targets as well. In contrast, there is a sparse region in the network, where anti-186 infectives hit some of the targets including in particular VEGFR2. Ibrutinib is the exception to cancer 187 drugs targeting only two targets.
188
The dense region of cancer drugs in the network may be due to their chemical similarity and resulting 189 similar target profiles. Conversely, it can be expected that anti-infectives will have very different scaffolds.
190
To understand this relation in detail, we compared the chemical structure of all 42 drugs against each other.
191
Consider Figure 4 with the drugs' structure. Visual inspection already reveals some similar scaffolds. As anti-cancer drug structurally close to many of the known drugs but not a known binder to any of the targets 212 according to BindingDB. Furthermore, suramin, an anti-infective shows some weak structural similarity to 213 the cancer drug mitoxantrone. The former has only very few targets, while the latter is highly promiscuous. These examples not only document scaffold hopping from pazopanib to ibrutinib and from nintenadib 231 to suramin, but also target hopping from parasitic CDPK1 to human VEGFR2 and from plant RDM1 to 232 human VEGFR2. These jumps in target space are large. They cross family and species boundaries. As 233 such they illustrate the limited space of binding sites, which was eluded to in the introduction.
234
Ibrutinib inactivates B-cells. In a final validation step, we tested the drugs' ability to impede B-cell's The top ten targets are suitable for structure-based drug repositioning screening. For 10 targets (number 11 to 20) no structural were available and thus these target could not be used for structure -based drug repositioning. Silencing of all listed targets leads to strong the downregulation of CD70 and CD80 expressions in the B cell Namalwa cell line activated by the TLR9 agonist ODN2006 without causing cell death (column cell survival). A literature study links nearly all targets to cancer and some to autoimmune diseases or cancer of the immune system (IS). Overall, there are many novel autoimmune targets and KDR (VEGFR2) emerges as very promising target with 36 protein structures, potent decrease in expression of CD70 and CD80 following knock out of target in activated Namalwa cells without affecting cell viability and links to both cancer and auto-immunity. Table 2 : List of new drug-target interactions predicted by interaction profile similarity and confirmed by experimental kinase activity assay. Enzyme activity was measured at a compound concentration of 1µM and 10µM. Drugs able to lower the enzyme activity to less than 50% (above dashed line) at 10µM were defined as strong inhibitors while drugs that lowered kinase activity at 10µM between 50% and 70% (below dashed line) were classified as weak inhibitors. Discarding the disinfectant Hexachlorophene because of its low medical interest, two compounds have been highlighted for showing inhibition at both 1µM and 10µM, ibrutinib and suramin . tight network of cancer drugs and targets while there is only one known autoimmune compound, which binds, however, many of the cancer targets. VEGR2, the promising autoimmune target, we identified, is inhibited by cancer and anti-infection drugs. 
